Pharmaceuticals, Biotechnology and Life Sciences
Progenity has named new Chief Commercial Officer, boosting its capacity in executive leadership team.
Phillips-Medisize has won a contract to produce first electronic-enabled combination drug delivery product, which is a post-phase 3 developement stage…
RALEIGH, N.C.–(BUSINESS WIRE)– SignalPath, a healthcare technology company reimagining the execution of clinical trials, announces the closing of their Series…
PRINCETON, N.J. & SAN DIEGO–(BUSINESS WIRE)–Sonnet BioTherapeutics Inc., a clinical stage biopharmaceutical developing innovative targeted biologic drugs, announced today that…
NOTTINGHAM, England–(BUSINESS WIRE)–Quotient Sciences, the innovative drug development and manufacturing organization, today announces the appointment of Claes Glassell as non-executive…
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–#AI— Systems Oncology, LLC (“SO”) and The Pritzker Organization, LLC (“TPO”) announced today that Pritzker Family Business Interests…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced…
NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces the clearance…
Bristol-Myers Squibb study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the…
Novartis has ended third quarter 2019 with reported net income of $2.0 billion, which as an 8% increase, driven by higher operating income and higher income from associated companies, saying in the press release Tuesday that its EPS was USD 0.90 (+11%, +14% cc), growing faster than net income driven by lower weighted average number of shares outstanding.